Literature DB >> 9070853

Identification of the extracellular domains of Flt-1 that mediate ligand interactions.

S A Cunningham1, C C Stephan, M P Arrate, K G Ayer, T A Brock.   

Abstract

Vascular Endothelial Growth Factor (VEGF) mediates its actions through the Flt-1 and KDR(Flk-1) receptor tyrosine kinases. To localize the extracellular region of Flt-1 that is involved in ligand interactions, we prepared secreted fusion proteins between various combinations of its seven extracellular IgG-like folds. Ligand binding studies show that in combination, domains one and two (amino acids 1-234) are sufficient to achieve VEGF165 interactions. Either domain alone is insufficient to achieve this effect. However, Scatchard analysis reveals that despite the binding capabilities of this construct, the Kd is five fold lower than ligand binding to the full extracellular domain. We find that addition of domain three to this minimal site restores high affinity receptor binding. Further, we show that domains one and two are sufficient to achieve interactions of Flt-1 with Placental Growth Factor (PIGF-1).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9070853     DOI: 10.1006/bbrc.1997.6156

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies.

Authors:  Yan Gong; Eric Bourhis; Cecilia Chiu; Scott Stawicki; Venita I DeAlmeida; Bob Y Liu; Khanhky Phamluong; Tim C Cao; Richard A D Carano; James A Ernst; Mark Solloway; Bonnee Rubinfeld; Rami N Hannoush; Yan Wu; Paul Polakis; Mike Costa
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

Review 2.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

Review 3.  Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.

Authors:  Z Zhu; L Witte
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.